Efficacy and safety of Brentuximab Vedotin in advanced cutaneous T-Cell lymphomas patients

被引：1
|
作者：
Papadavid, E. [1 ]
Kapniari, E. [1 ]
Marinos, L. [2 ]
Nikolaou, V. [3 ]
Oikonomidi, A. [3 ]
Georgakopoulos, J. [4 ]
Stratigos, A. [3 ]
Kouloulias, V. [4 ]
Pappa, V. [5 ]
机构：
[1] Univ Athens, Dept Dermatol Venereol 2, Attikon Gen Univ Hosp, Athens, Greece
[2] Evaggelismos Gen Hosp, Hemato Pathol Dept, Athens, Greece
[3] Univ Athens, Syggros Hosp, Dept Dermatol Venereol 1, Athens, Greece
[4] Univ Athens, Attikon Gen Univ Hosp, Dept Radiol 2, Radiol Oncol, Athens, Greece
[5] Univ Athens, Attikon Gen Univ Hosp, Propedeut Dept 2, Hematol Unit, Athens, Greece
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2019年 / 33卷 / 05期
关键词：
MYCOSIS-FUNGOIDES;
D O I：
10.1111/jdv.15409
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：E223 / E225
页数：4
相关论文
共 50 条
  • [21] Brentuximab vedotin in systemic T-cell lymphoma
    Oki, Yasuhiro
    Younes, Anas
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (05) : 623 - 632
  • [22] Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
    Horwitz, Steven M.
    Advani, Ranjana H.
    Bartlett, Nancy L.
    Jacobsen, Eric D.
    Sharman, Jeff P.
    O'Connor, Owen A.
    Siddiqi, Tanya
    Kennedy, Dana A.
    Oki, Yasuhiro
    BLOOD, 2014, 123 (20) : 3095 - 3100
  • [23] The efficacy and safety of brentuximab vedotin for peripheral T-cell lymphoma: A systemic review and meta-analysis
    Li, Jiarun
    Tang, Shuhan
    Liu, Jinyi
    Huang, Ruihao
    Rao, Jun
    Gao, Li
    Wang, Xiaoqi
    Zhang, Xi
    JOURNAL OF INVESTIGATIVE MEDICINE, 2025, 73 (01) : 156 - 171
  • [24] Real-world evidence study of brentuximab vedotin retreatment in patients with cutaneous T-cell lymphoma
    Mitteldorf, C.
    de Masson, A.
    Beylot-Barry, M.
    Wobster, M.
    Zomas, A.
    Stache, V.
    Assaf, C.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S77 - S78
  • [25] Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma
    Zinzani, Pier Luigi
    Salles, Gilles
    Moskowitz, Alison J.
    Santoro, Armando
    Mehta, Amitkumar
    Barr, Paul M.
    Mehta-Shah, Neha
    Collins, Graham P.
    Ansell, Stephen M.
    Brody, Joshua D.
    Domingo-Domenech, Eva
    Johnson, Nathalie A.
    Cunningham, David
    Ferrari, Silvia
    Lisano, Julie
    Krajewski, Jennifer
    Wen, Rachael
    Akyol, Alev
    Crowe, Russell
    Savage, Kerry J.
    BLOOD ADVANCES, 2024, 8 (10) : 2400 - 2404
  • [26] EFFICACY AND SAFETY OF ORAL BEXAROTENE IN THE TREATMENT OF PRIMARY CUTANEOUS T-CELL LYMPHOMAS
    Lugtenburg, P.
    Kruip, M.
    Ibrahim, F.
    de Vijlder, H.
    de Haas, E.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 641 - 642
  • [27] Cutaneous Gamma-Delta T-Cell Lymphoma Successfully Treated With Brentuximab Vedotin
    Rubio-Gonzalez, Belen
    Zain, Jasmine
    Garcia, Lino
    Rosen, Steven T.
    Querfeld, Christiane
    JAMA DERMATOLOGY, 2016, 152 (12) : 1388 - 1390
  • [28] COST-EFFECTIVENESS OF BRENTUXIMAB VEDOTIN FOR THE FRONTLINE TREATMENT OF PERIPHERAL T-CELL LYMPHOMAS IN CANADA
    Zou, D.
    Lee, J.
    Kansal, A.
    Ma, W.
    Harris, M.
    Lisano, J.
    Fenton, K.
    Yu-Isenberg, K.
    VALUE IN HEALTH, 2020, 23 : S444 - S444
  • [29] Efficacy of Brentuximab-Vedotin (BV) in Peripheral T-Cell Lymphomas (PTCLs) Other Than Anaplastic Large Cell Lymphoma (ALCL)
    Zannori, Cristina
    Martiniani, Roberta
    Ascani, Stefano
    Liberati, Fabrizio
    Rauco, Annamaria
    Genua, Angelo
    Liberati, Anna Marina
    BLOOD, 2016, 128 (22)
  • [30] Brentuximab vedotin for treatment of systemic T-cell lymphoma
    Chihara, Dai
    Oki, Yasuhiro
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (10) : 1519 - 1526
12345